Neoplastic transformation of rat liver epithelial cells is enhanced by non-transferrin-bound iron
© Messner and Kowdley; licensee BioMed Central Ltd. 2008
Received: 11 August 2007
Accepted: 06 February 2008
Published: 06 February 2008
Iron overload is associated with liver toxicity, cirrhosis, and hepatocellular carcinoma in humans. While most iron circulates in blood as transferrin-bound iron, non-transferrin-bound iron (NTBI) also becomes elevated and contributes to toxicity in the setting of iron overload. The mechanism for iron-related carcinogenesis is not well understood, in part due to a shortage of suitable experimental models. The primary aim of this study was to investigate NTBI-related hepatic carcinogenesis using T51B rat liver epithelial cells, a non-neoplastic cell line previously developed for carcinogenicity and tumor promotion studies.
T51B cells were loaded with iron by repeated addition of ferric ammonium citrate (FAC) to the culture medium. Iron internalization was documented by chemical assay, ferritin induction, and loss of calcein fluorescence. Proliferative effects were determined by cell count, toxicity was determined by MTT assay, and neoplastic transformation was assessed by measuring colony formation in soft agar. Cyclin levels were measured by western blot.
T51B cells readily internalized NTBI given as FAC. Within 1 week of treatment at 200 μM, there were significant but well-tolerated toxic effects including a decrease in cell proliferation (30% decrease, p < 0.01). FAC alone induced little or no colony formation in soft agar. In contrast, FAC addition to cells previously initiated with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) resulted in a concentration dependent increase in colony formation. This was first detected at 12 weeks of FAC treatment and increased at longer times. At 16 weeks, colony formation increased more than 10 fold in cells treated with 200 μM FAC (p < 0.001). The iron chelator desferoxamine reduced both iron uptake and colony formation. Cells cultured with 200 μM FAC showed decreased cyclin D1, decreased cyclin A, and increased cyclin B1.
These results establish NTBI as a tumor promoter in T51B rat liver epithelial cells. Changes in cyclin proteins suggest cell cycle disregulation contributes to tumor promotion by NTBI in this liver cell model.
Iron is an essential metal, but is potentially toxic and therefore tightly regulated in mammalian systems [1, 2]. Most body iron stores are sequestered in a non-toxic form through high affinity binding to transport and storage proteins including transferrin and ferritin. There is also a significant pool of "free iron" complexed to low molecular weight (MW) carriers such as citrate. Intracellular free iron is a necessary intermediate between iron storage depots and biosynthetic pathways that utilize iron. It also mediates translational control of iron homeostasis by binding to iron regulatory proteins. However, free iron can undergo redox cycling, forming reactive oxygen species (ROS) through the Fenton and Haber Weiss reactions [3–5]. ROS damage biomolecules and cause oxidative stress by depleting cellular antioxidant stores and may result in cell death [6–8]. The potential for iron damage is particularly high in liver, the primary organ for storage of excess iron . As there is no significant excretion of iron, excess uptake may be accompanied by severe liver damage that progresses to liver failure or hepatocellular carcinoma (HCC) . This occurs in diseases of iron overload, including hereditary hemochromatosis. Elevated liver iron is also associated with increased HCC in other liver diseases, including biliary cirrhosis and hepatitis C .
Iron overload is marked by increases in both transferrin-bound and free, non-transferrin-bound iron (NTBI) in blood [11, 12]. Several considerations suggest these two forms are separable: (1) Although transferrin-bound iron has significant growth-promoting effects, stimulation of cell growth by NTBI was seen only over a narrow concentration range and under transferrin-limiting conditions [13, 14]. Tumor cells, which can have increased growth rates, frequently have increased levels of transferrin receptors , and iron uptake via this route is higher than in neighboring cells. Yet in iron overload, tumors contain lower iron levels than surrounding liver tissue . Similarly bone marrow cells, with a higher level of transferrin receptors than hepatocytes, do not accumulate iron in iron overload diseases. (2) Humans and animals that lack transferrin still develop iron overload . (3) There are many reports of experimental iron overload in cells and animals given NTBI [6–8], but not transferrin-bound iron. (4) Rodent studies identified transferrin-independent pathways of iron uptake in liver [18, 19]. This was confirmed in rat hepatocytes and other mammalian cell types in culture [20–23]. (5) Finally, unlike transferrin uptake via receptor-mediated endocytosis, NTBI uptake was not downregulated in iron replete cells; it increased with exposure to iron [24–26]. In addition, NTBI uptake in liver increased in an animal model of hemochromatosis . These points suggest that mechanisms that don't involve transferrin receptors are critical for iron overload in liver. NTBI is an important, and possibly the primary, source of iron-related toxicity in liver.
Although transferrin-independent uptake and toxicity of NTBI have been demonstrated in animals and in cultured cells, effects on neoplastic transformation are not understood. This is due partly to a lack of suitable experimental models, and partly to the difficulty of obtaining effects using physiological forms of NTBI. The high rate of HCC among human hemochromatosis patients with cirrhosis has not been replicated in animal models of this disease [2, 9]. Non-physiological forms of dietary iron contributed to liver cancer in animals [28, 29], but the relevance to biological iron is unknown. Similarly, prior reports that iron acts as a co-carcinogen or tumor promoter in liver and cultured cells also depended on non-physiological iron ligands [16, 30, 31]. In some protocols iron inhibited or had no effect on cell transformation [32, 33]. Transformation protocols that require any form of iron have not been established in human cells. No previous studies have reported transformation-related effects of iron administered in a form that is present in humans.
Ferric citrate is present in blood and its levels increase in hereditary hemochromatosis [12, 34]. It may be an important contributor to the pathological effects of iron overload in humans, including hepatocellular carcinoma. Ferric ammonium citrate (FAC) is a formulation that minimizes generation of insoluble iron hydroxides in vitro . The present study investigated the transforming effects of this physiologically and pathologically relevant form of NTBI. We utilized T51B rat liver epithelial cells, a well-characterized model for tumor promotion and carcinogenicity studies. We found FAC has properties of a tumor promoter, rather than a complete carcinogen. Iron-induced changes in cyclin proteins suggest tumor promotion results in part from disruptions in regulation of the T51B cell cycle in proliferating cells.
N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), ferric ammonium citrate (FAC), desferoxamine, and calcein-AM were from Sigma/Aldrich (St. Louis, MO). Newborn calf serum was from Atlanta Biologicals (Norcross GA). Other cell culture reagents were from GIBCO/Invitrogen (Carlsbad, CA). Agarose was from Cambrex BioScience (Rockland, ME). Antibodies and other specialty reagents were from commercial sources as noted below. Concentrated stock solutions were prepared assuming 100% reagent purity and stored in aliquots at -20°C. Solutions in solvent were kept at -20°C until use, while aqueous reagents were used after thawing and storage at 4°C for limited periods. As appropriate, control experiments were run to document that solvent alone had no effect. MNNG stock solutions were freshly prepared just prior to use.
Cell culture and transformation assays
T51B cells are a non-neoplastic cell line derived from rat liver and used in studies of carcinogenicity and tumor promotion [36–39]. T51B cells were maintained in Eagles basal media supplemented with 10% newborn calf serum, 2 mM l-glutamine, and 100 U/ml penicillin/streptomycin (complete media), at 37°C in a 5% CO2 atmosphere. For proliferation and all other assays, treatment was started 1 day after plating. In general, untreated cells reached confluence 5 days after plating and were subsequently quiescent . Cell number was determined at 3 days treatment (to approximate log phase growth rate) and at 7 days treatment (to approximate saturation density) by trypsinization and counting with a hemocytometer. Control experiments demonstrated >95% of the cells were viable as determined by trypan blue exclusion. Multiple replicates were compiled for statistical analysis and presentation. To determine differences between untreated and FAC-treated groups, the data were evaluated using a 2 tailed unpaired student t-test for samples with unequal variance, and significance noted at p < 0.01 and p < 0.001 levels.
Toxicity assays used the MTT method  in a 96 well plate format at an initial seeding density of 10,000 cells per well. Treatments were initiated 1 day after plating and renewed in fresh complete media after 2 days. After treatment for 5 days, cells were rinsed with PBS and incubated with 0.3 μg/ml methylthiazolyldiphenyl-tetrazolium bromide (MTT) in complete media containing 10 mM HEPES pH7.4 for 3 hours. The formazan product was solubilized in DMSO and measured by absorbance at 540 nm. Statistical evaluations (to compare treated to untreated cells cultured in parallel) were performed as described above for cell proliferation.
For the transformation assays, the cells were treated with or without 0.5 μg/ml MNNG one day after plating. After 24 hours, the media was renewed and test treatments initiated. Cells receiving MNNG only were cultured in complete media for the same times as cells receiving test tumor promotion treatments. The cells were passaged every 2 weeks during the transformation experiments, and the media/treatments were further renewed 3–4 times between each splitting. Starting at 12 weeks, aliquots of cells were plated in soft agar to assess transformation . Specifically, colony formation in soft agar was measured after 12, 14, and 16 weeks in monolayer culture (experiment 1); after 12, 14, 16, 18, and 20 weeks (experiment 2); and after 12, 14, 16, and 18 weeks (experiments 3 and 4). An aliquot corresponding to 25,000 cells prepared in 0.35% top agar media (agarose in Iscove's DMEM containing 10% newborn calf serum and 10 ng/ml epidermal growth factor) was layered on 0.6% bottom agar media in a 60 mm dish. After 3 weeks the colonies were stained with 1 ml 0.5 mg/ml iodonitrotetrazolium violet and counted under the microscope. Colonies larger than 0.17 mm in diameter (approximately 100 cells) were scored as positive. The means and standard error of the means (s.e.m.) were determined from quadruplicate soft agar plates in single experiments or after compiling data from multiple experiments as specified. For clarity, data from selected but representative time points are presented for some experiments. Statistical evaluations (to compare experimental to control cells cultured in parallel) were performed as described above for cell proliferation.
Total non-heme iron content of cells was determined using ferrozine  as follows. Cells were rinsed in PBS on ice, and then lysed and scraped in deionized water. One volume of buffer A (1 M HCl 10%TCA) was added and the sample was heated at 95°C for 30–45 minutes. Samples were cooled to room temperature and the protein precipitate removed by centrifugation for 10 minutes at 14,000 × g. An aliquot of the supernatant was mixed with 1 volume of buffer B (0.58 mM ferrozine, 1.5% thioglycolic acid, 1.5 M sodium acetate) and incubated for 30 minutes at room temperature. The absorbance of samples at 570 nm was compared in duplicate to an NIST-traceable iron reference (Fluka) standard curve run in parallel. Approximately 0.75 nmol iron was required to achieve less than 10% deviation from the standard curve, corresponding to a limit of detection of roughly 2 nmol/mg protein. The non-heme iron content of untreated control cells was below this limit and must be considered an approximation. Qualitatively similar results, but with less sensitivity, were obtained using the bathophenanthroline disulfonate assay . Cell lysate protein was determined relative to BSA by a modified Lowry assay. Procedures for western blot analysis, including cell harvesting, have been described [38, 42]. Antibodies to ferritin heavy and light chains, cyclin B1, cyclin D1, cyclin E, and GAPDH, were from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to cyclin A were from Oncogene Research Products (Cambridge, MA). Secondary antibodies linked to horseradish peroxidase were from Jackson Immunoresearch (West Grove, PA). Detection utilized the ECL-plus system from Amersham/GE Healthcare (Arlington Heights, IL).
Calcein fluorescence in cells was assessed by epifluorescence microscopy. Cells plated on glass coverslips were treated for 30 minutes with 0.25 μg/ml calcein-AM (Sigma) in serum-free media, rinsed, and incubated in complete media with or without FAC and dfo for the times indicated. The fluorescence of intracellular calcein is quenched by the influx of free iron. Although calcein may also be partially degraded by iron under certain conditions , this would minimally require iron uptake by the cells. Loss of calcein fluorescence by either mechanism (quenching or degradation) indicates iron influx. The coverslips were rinsed 3× in PBS, mounted using Vectashield (Vector Laboratories, Burlingame, CA), and viewed with a Nikon Eclipse 50i inverted microscope equipped with X-cite 120 epifluorescence. For each treatment condition, identical fields were photographed with a Nikon Coolpix 4500 digital camera to record FITC fluorescence and phase contrast views. Constant photographic parameters (exposure, contrast, magnification, etc.) were maintained for all treatment conditions.
Non-transferrin bound iron uptake in T51B cells
FAC acts as a tumor promoter in T51B cells
Transformation of T51B cells by MNNG and FAC1.
Number of colonies per 25,000 cells
0.0 (+/- 0.0)
1.3 (+/- 0.8)
1.5 (+/- 0.5)
4.3 (+/- 1.0)
1.8* (+/- 0.2)
17.5 (+/- 3.3)
1.8 (+/- 1.4)
21.5* (+/- 2.1)
3.0 (+/- 1.4)
5.3 (+/- 1.3)
Time dependence of tumor promotion by iron.
Number of soft agar colonies per 25,000 cells1
50 μM FAC
0.8 (+/- 0.5)
0.8 (+/- 0.5)
3.5 (+/- 1.2)
2.3 (+/- 0.5)
4.0 (+/- 2.0)
50 μM FAC
7.5 (+/- 1.4)
200 μM FAC
5.3 (+/- 1.2)
1.0 (+/- 0.4)
10.8 (+/- 2.4)
9.3 (+/- 1.0)
2.3 (+/- 1.2)
200 μM FAC
32.5 (+/- 8.5)
200 μM AmCit
1.5 (+/- 0.3)
0.0 (+/- 0.0)
1.3 (+/- 0.6)
0.0 (+/- 0.0)
0.3 (+/- 0.3)
200 μM AmCit
1.3 (+/- 0.5)
0.0 (+/- 0.0)
0.5 (+/- 0.3)
0.0 (+/- 0.0)
0.7 (+/- 0.7)
Iron loading elicits changes in cell cycle proteins in T51B cells
The current study demonstrated that FAC acts as a tumor promoter in T51B liver cells. We also found tumor-promoting concentrations of FAC decreased, rather than increased, the proliferation of normal T51B cells. To our knowledge, this is the first report to describe tumor promotion by a physiologically and pathologically relevant form of iron. This is an important point missing from earlier studies of iron overload and neoplastic transformation. Previous experiments used various non-physiological chelating ligands to increase the bioavailability of iron. For example, carbonyl iron caused moderate iron overload in rats, but ferrocene was required for severe iron overload, liver neoplasms, and HCC [28, 29]. Iron given as the nitrilotriacetate (NTA) complex caused DNA damage and transformation of cells in culture, whereas iron citrate did not [31, 48, 49]. Iron-NTA was a liver tumor promoter in rats . Co-administration of an iron ionophore significantly increased iron effects . Until now it was unclear whether ionic iron alone had transformation-related effects in a mammalian system. Our finding, that FAC had tumor promotion activity in the absence of non-physiological chelating ligands, settles this dispute. This has potential clinical implications, as the goal to reduce the incidence of HCC among iron overload patients may be accomplished through long-term reduction of iron levels . Novel strategies that target NTBI may be particularly effective in achieving this goal.
By definition, tumor promotion involves the selective proliferation of pre-neoplastic (vs. normal) cells. Classical tumor promoters such as phorbol 12-myristate 13-acetate (TPA) increase DNA synthesis and cell proliferation in cell and animal models of carcinogenesis . This mitogenic effect is thought to be critical for tumor promotion, acting by positive selection to increase proliferation of initiated cells. Cell proliferation is needed to fix and clonally expand carcinogenic mutations resulting from chemically-induced DNA damage. Alternatively, a tumor promoter may cause growth inhibition and/or cell toxicity, accompanied by outgrowth of a resistant phenotype. This idea was first proposed for liver by Farber and co-workers [51, 52] as the "resistant hepatocyte model" of tumor promotion. Similarly, a role for compensatory proliferation in liver tumor promotion has been proposed [53, 54]. Essentially, a certain degree of cell toxicity is tumor promoting in liver because it allows for compensatory proliferation of chemically initiated cells, which would otherwise remain quiescent. These previously described negative selection models are consistent with our findings and offer insight into how NTBI may contribute to HCC in iron overload. We propose that anti-proliferative or other toxic effects of iron loading on normal cells, rather than mitogenic effects on pre-neoplastic cells, explain tumor promotion in the T51B cell model. Consequently, agents which prevent NTBI toxicity are predicted to also block tumor promotion.
HCC may originate from hepatocytes or oval cells, a precursor stem cell type in liver [55–61]. Differentiated hepatocytes do not readily proliferate in culture, and so are not suitable for the type of study presented here. To model iron-related HCC, therefore, we used T51B cells, a cell type similar to liver oval cells. In addition, we used 50–200 μM FAC for 12–16 weeks to establish iron overload. Although development of HCC in humans with hemochromatosis occurs at lower serum iron citrate concentrations (5–20 μM) over several decades [9, 11, 12, 62, 63], several considerations suggest our experimental conditions are appropriate. First, studies of serum NTBI in humans are only partially informative. Iron citrate (unlike transferrin iron) is very rapidly cleared from the blood by the liver , and so the serum concentration likely underestimates liver exposure. Second, iron-related HCC occurs primarily in the setting of liver cirrhosis. The effect of cirrhosis on iron citrate concentrations in the liver itself is unknown, but exposure of preneoplastic cells to levels higher than reported in blood seems possible. Finally, studies of high concentrations of carcinogens and tumor promoters given for short times are generally accepted as useful predictors of effects caused by exposure to lower concentrations for longer times. These points argue that findings from the T51B cell model are applicable to the promotion phase of iron-related HCC in humans.
The route of NTBI uptake in T51B cells is unknown, but there are several possibilities. The divalent metal transporter DMT-1 (NRAMP2) is thought to be important in most cell types [2, 64–66]. This protein has been localized to the cell surface in hepatocytes , and iron transport at pH 7.4 has been documented . However, iron transport by DMT-1 is optimal near pH 5.5, consistent with a primary function in recovery of iron released from transferrin in endosomes. In AML12 hepatocytes, the cell surface zinc transporter zip14 is an additional pathway . This protein is particularly interesting with respect to neoplastic transformation, as zip14 was reported to be under expressed in HCC . Downregulation of NTBI uptake is one potential mechanism by which initiated cells could minimize iron-related toxicity and gain a proliferative advantage over normal cells in our model. Alternate NTBI uptake pathways identified in other cell types include the TRP family of cell surface non-selective cation channels , and L-type calcium channels .
At present, we surmise that NTBI toxicity impaired progression of T51B cells into or through mitosis, based on high levels of cyclin B1. ROS generated by a Fenton-type reaction involving vanadate was shown previously to cause increased cyclin B and M-phase arrest [72, 73]. Decreases in cyclins D1 and A are expected if proliferating cells become delayed at this point in the cycle. Importantly, these changes were evident at tumor promoting concentrations of FAC (200 μM). Relatively minor phenotypic distinctions may allow pre-neoplastic initiated cells to evade the selective pressure exerted by FAC at this concentration. However, these distinctions were insufficient to overcome additional toxic effects of higher concentrations, since tumor promotion decreased at 500 μM FAC. The cause(s) of increased cyclin B and cell cycle delay are unknown; dissecting potential mechanisms is a goal of future experiments. The step taken here, of demonstrating that these changes are caused by a physiologically and pathologically relevant form of NTBI under conditions of tumor promotion, is a critical one towards understanding and preventing iron-related carcinogenesis in humans.
We conclude that NTBI is a tumor promoter, but not a complete carcinogen, in T51B rat liver epithelial cells. This study is the first demonstration that a form of iron present in humans has cancer-related effects. It defines an experimental model for future studies on mechanism and prevention of iron-related liver cancer.
We thank Dr. Gowsala Sivam of Bastyr University for support and advice during this study. This research was supported in part by an NIH grant from the Institute of Diabetes and Digestive and Kidney Diseases (K24 DK02957 to KVK). DJM was supported by a training grant to Bastyr University (T32 AT00815) from the National Center for Complementary and Alternative Medicine.
- Hentze MW, Muckenthaler MU, Andrews NC: Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004, 117 (3): 285-297. 10.1016/S0092-8674(04)00343-5.View ArticlePubMed
- Andrews NC, Schmidt PJ: Iron homeostasis. Annu Rev Physiol. 2007, 69: 69-85. 10.1146/annurev.physiol.69.031905.164337.View ArticlePubMed
- Huang X: Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res. 2003, 533 (1–2): 153-171.View ArticlePubMed
- Fenton H: Oxidation of tartaric acid in presence of iron. J Chem Soc. 1894, 65: 899-910.View Article
- Haber F, Weiss J: The catalytic decompostion of hydrogen peroxide by iron salts. Proc Royal Society London Section A. 1934, 147: 332-351.View Article
- Stal P: Iron as a hepatotoxin. Dig Dis. 1995, 13 (4): 205-222.View ArticlePubMed
- Eaton JW, Qian M: Molecular bases of cellular iron toxicity. Free Radic Biol Med. 2002, 32 (9): 833-840. 10.1016/S0891-5849(02)00772-4.View ArticlePubMed
- Valko M, Morris H, Cronin MT: Metals, toxicity and oxidative stress. Curr Med Chem. 2005, 12 (10): 1161-1208. 10.2174/0929867053764635.View ArticlePubMed
- Kowdley KV: Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004, 127 (5 Suppl 1): S79-86. 10.1016/j.gastro.2004.09.019.View ArticlePubMed
- Ko C, Siddaiah N, Berger J, Gish R, Brandhagen D, Sterling RK, Cotler SJ, Fontana RJ, McCashland TM, Han SH, et al: Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int. 2007, 27 (10): 1394-1401.View ArticlePubMed
- Beutler E: Hemochromatosis: genetics and pathophysiology. Annu Rev Med. 2006, 57: 331-347. 10.1146/annurev.med.57.121304.131310.View ArticlePubMed
- Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ: Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem. 1989, 264 (8): 4417-4422.PubMed
- Goto Y, Paterson M, Listowsky I: Iron uptake and regulation of ferritin synthesis by hepatoma cells in hormone-supplemented serum-free media. J Biol Chem. 1983, 258 (8): 5248-5255.PubMed
- Hann HW, Stahlhut MW, Hann CL: Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology. 1990, 11 (4): 566-569. 10.1002/hep.1840110407.View ArticlePubMed
- Daniels TR, Delgado T, Helguera G, Penichet ML: The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006, 121 (2): 159-176. 10.1016/j.clim.2006.06.006.View ArticlePubMed
- Deugnier Y, Turlin B: Iron and hepatocellular carcinoma. J Gastroenterol Hepatol. 2001, 16 (5): 491-494. 10.1046/j.1440-1746.2001.02430.x.View ArticlePubMed
- Trenor CC, Campagna DR, Sellers VM, Andrews NC, Fleming MD: The molecular defect in hypotransferrinemic mice. Blood. 2000, 96 (3): 1113-1118.PubMed
- Brissot P, Wright TL, Ma WL, Weisiger RA: Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest. 1985, 76 (4): 1463-1470. 10.1172/JCI112125.PubMed CentralView ArticlePubMed
- Wright TL, Brissot P, Ma WL, Weisiger RA: Characterization of non-transferrin-bound iron clearance by rat liver. J Biol Chem. 1986, 261 (23): 10909-10914.PubMed
- Sturrock A, Alexander J, Lamb J, Craven CM, Kaplan J: Characterization of a transferrin-independent uptake system for iron in HeLa cells. J Biol Chem. 1990, 265 (6): 3139-3145.PubMed
- Oshiro S, Nakajima H, Markello T, Krasnewich D, Bernardini I, Gahl WA: Redox, transferrin-independent, and receptor-mediated endocytosis iron uptake systems in cultured human fibroblasts. J Biol Chem. 1993, 268 (29): 21586-21591.PubMed
- Trinder D, Morgan E: Mechanisms of ferric citrate uptake by human hepatoma cells. Am J Physiol. 1998, 275 (2 Pt 1): G279-286.PubMed
- Baker E, Baker SM, Morgan EH: Characterisation of non-transferrin-bound iron (ferric citrate) uptake by rat hepatocytes in culture. Biochim Biophys Acta. 1998, 1380 (1): 21-30.View ArticlePubMed
- Parkes JG, Randell EW, Olivieri NF, Templeton DM: Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells. Biochim Biophys Acta. 1995, 1243 (3): 373-380.View ArticlePubMed
- Richardson DR, Ponka P: Identification of a mechanism of iron uptake by cells which is stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction. Biochim Biophys Acta. 1995, 1269 (2): 105-114. 10.1016/0167-4889(95)00096-B.View ArticlePubMed
- Scheiber-Mojdehkar B, Zimmermann I, Dresow B, Goldenberg H: Differential response of non-transferrin bound iron uptake in rat liver cells on long-term and short-term treatment with iron. J Hepatol. 1999, 31 (1): 61-70. 10.1016/S0168-8278(99)80164-0.View ArticlePubMed
- Chua AC, Olynyk JK, Leedman PJ, Trinder D: Nontransferrin-bound iron uptake by hepatocytes is increased in the Hfe knockout mouse model of hereditary hemochromatosis. Blood. 2004, 104 (5): 1519-1525. 10.1182/blood-2003-11-3872.View ArticlePubMed
- Asare GA, Paterson AC, Kew MC, Khan S, Mossanda KS: Iron-free neoplastic nodules and hepatocellular carcinoma without cirrhosis in Wistar rats fed a diet high in iron. J Pathol. 2006, 208 (1): 82-90. 10.1002/path.1875.View ArticlePubMed
- Asare GA, Mossanda KS, Kew MC, Paterson AC, Kahler-Venter CP, Siziba K: Hepatocellular carcinoma caused by iron overload: a possible mechanism of direct hepatocarcinogenicity. Toxicology. 2006, 219 (1–3): 41-52. 10.1016/j.tox.2005.11.006.View ArticlePubMed
- Iqbal M, Giri U, Athar M: Ferric nitrilotriacetate (Fe-NTA) is a potent hepatic tumor promoter and acts through the generation of oxidative stress. Biochem Biophys Res Commun. 1995, 212 (2): 557-563. 10.1006/bbrc.1995.2006.View ArticlePubMed
- Yamada M, Awai M, Okigaki T: Rapid in vitro transformation system for liver epithelial cells by iron chelate, Fe-NTA. Cytotechnology. 1990, 3 (2): 149-156. 10.1007/BF00143677.View ArticlePubMed
- Lemmer ER, Gelderblom WC, Shephard EG, Abel S, Seymour BL, Cruse JP, Kirsch RE, Marasas WF, Hall PM: The effects of dietary iron overload on fumonisin B1-induced cancer promotion in the rat liver. Cancer Lett. 1999, 146 (2): 207-215. 10.1016/S0304-3835(99)00274-8.View ArticlePubMed
- Stal P, Hultcrantz R, Moller L, Eriksson LC: The effects of dietary iron on initiation and promotion in chemical hepatocarcinogenesis. Hepatology. 1995, 21 (2): 521-528.PubMed
- Wheby MS, Umpierre G: Effect of Transferrin Saturation on Iron Absorption in Man. N Engl J Med. 1964, 271: 1391-1395.View ArticlePubMed
- Leanderson P, Tagesson C: Iron bound to the lipophilic iron chelator, 8-hydroxyquinoline, causes DNA strand breakage in cultured lung cells. Carcinogenesis. 1996, 17 (3): 545-550. 10.1093/carcin/17.3.545.View ArticlePubMed
- Swierenga SH, Whitfield JF, Boynton AL, MacManus JP, Rixon RH, Sikorska M, Tsang BK, Walker PR: Regulation of proliferation of normal and neoplastic rat liver cells by calcium and cyclic AMP. Ann N Y Acad Sci. 1980, 349: 294-311. 10.1111/j.1749-6632.1980.tb29534.x.View ArticlePubMed
- Boynton AL, Kleine LP, Whitfield JF: Relation between colony formation in calcium-deficient medium, colony formation in soft agar, and tumor formation by T51B rat liver cells. Cancer Lett. 1984, 21 (3): 293-302. 10.1016/0304-3835(84)90008-9.View ArticlePubMed
- Messner DJ, Ao P, Jagdale AB, Boynton AL: Abbreviated cell cycle progression induced by the serine/threonine protein phosphatase inhibitor okadaic acid at concentrations that promote neoplastic transformation. Carcinogenesis. 2001, 22 (8): 1163-1172. 10.1093/carcin/22.8.1163.View ArticlePubMed
- Huang RP, Peng A, Golard A, Hossain MZ, Huang R, Liu YG, Boynton AL: Hydrogen peroxide promotes transformation of rat liver non-neoplastic epithelial cells through activation of epidermal growth factor receptor. Mol Carcinog. 2001, 30 (4): 209-217. 10.1002/mc.1030.View ArticlePubMed
- Sieuwerts AM, Klijn JG, Peters HA, Foekens JA: The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem. 1995, 33 (11): 813-823.PubMed
- Rebouche CJ, Wilcox CL, Widness JA: Microanalysis of non-heme iron in animal tissues. J Biochem Biophys Methods. 2004, 58 (3): 239-251. 10.1016/j.jbbm.2003.11.003.View ArticlePubMed
- Messner DJ, Romeo C, Boynton A, Rossie S: Inhibition of PP2A, but not PP5, mediates p53 activation by low levels of okadaic acid in rat liver epithelial cells. J Cell Biochem. 2006, 99 (1): 241-255. 10.1002/jcb.20919.View ArticlePubMed
- Hasinoff BB: The intracellular iron sensor calcein is catalytically oxidatively degraded by iron(II) in a hydrogen peroxide-dependent reaction. J Inorg Biochem. 2003, 95 (2–3): 157-164. 10.1016/S0162-0134(03)00099-0.View ArticlePubMed
- Huang RP, Peng A, Hossain MZ, Fan Y, Jagdale A, Boynton AL: Tumor promotion by hydrogen peroxide in rat liver epithelial cells. Carcinogenesis. 1999, 20 (3): 485-492. 10.1093/carcin/20.3.485.View ArticlePubMed
- Blouin R, Blouin MJ, Royal I, Grenier A, Roop DR, Loranger A, Marceau N: Cytokeratin 14 expression in rat liver cells in culture and localization in vivo. Differentiation. 1992, 52 (1): 45-54. 10.1111/j.1432-0436.1992.tb00498.x.View ArticlePubMed
- Colburn NH, Bruegge WF, Bates JR, Gray RH, Rossen JD, Kelsey WH, Shimada T: Correlation of anchorage-independent growth with tumorigenicity of chemically transformed mouse epidermal cells. Cancer Res. 1978, 38 (3): 624-634.PubMed
- Malumbres M, Barbacid M: Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005, 30 (11): 630-641. 10.1016/j.tibs.2005.09.005.View ArticlePubMed
- Hartwig A, Klyszcz-Nasko H, Schlepegrell R, Beyersmann D: Cellular damage by ferric nitrilotriacetate and ferric citrate in V79 cells: interrelationship between lipid peroxidation, DNA strand breaks and sister chromatid exchanges. Carcinogenesis. 1993, 14 (1): 107-112. 10.1093/carcin/14.1.107.View ArticlePubMed
- Hartwig A, Schlepegrell R: Induction of oxidative DNA damage by ferric iron in mammalian cells. Carcinogenesis. 1995, 16 (12): 3009-3013. 10.1093/carcin/16.12.3009.View ArticlePubMed
- Yuspa SH, Lichti U, Ben T, Patterson E, Hennings H, Slaga TJ, Colburn N, Kelsey W: Phorbol esters stimulate DNA synthesis and ornithine decarboxylase activity in mouse epidermal cell cultures. Nature. 1976, 262 (5567): 402-404. 10.1038/262402a0.View ArticlePubMed
- Farber E: Some emerging general principles in the pathogenesis of hepatocellular carcinoma. Cancer Surv. 1986, 5 (4): 695-718.PubMed
- Sarma DS, Rao PM, Rajalakshmi S: Liver tumour promotion by chemicals: models and mechanisms. Cancer Surv. 1986, 5 (4): 781-798.PubMed
- Fausto N: Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin Liver Dis. 1999, 19 (3): 243-252.View ArticlePubMed
- Maeda S, Kamata H, Luo JL, Leffert H, Karin M: IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005, 121 (7): 977-990. 10.1016/j.cell.2005.04.014.View ArticlePubMed
- Evarts RP, Nagy P, Marsden E, Thorgeirsson SS: A precursor-product relationship exists between oval cells and hepatocytes in rat liver. Carcinogenesis. 1987, 8 (11): 1737-1740. 10.1093/carcin/8.11.1737.View ArticlePubMed
- Evarts RP, Nagy P, Nakatsukasa H, Marsden E, Thorgeirsson SS: In vivo differentiation of rat liver oval cells into hepatocytes. Cancer Res. 1989, 49 (6): 1541-1547.PubMed
- Fausto N: Oval cells and liver carcinogenesis: an analysis of cell lineages in hepatic tumors using oncogene transfection techniques. Prog Clin Biol Res. 1990, 331: 325-334.PubMed
- Goyette M, Faris R, Braun L, Hixson D, Fausto N: Expression of hepatocyte and oval cell antigens in hepatocellular carcinomas produced by oncogene-transfected liver epithelial cells. Cancer Res. 1990, 50 (15): 4809-4817.PubMed
- Zhang N, Siegel K, Odenthal M, Becker R, Oesch F, Dienes HP, Schirmacher P, Steinberg P: The role of insulin-like growth factor II in the malignant transformation of rat liver oval cells. Hepatology. 1997, 25 (4): 900-905. 10.1002/hep.510250419.View ArticlePubMed
- Roskams TA, Libbrecht L, Desmet VJ: Progenitor cells in diseased human liver. Semin Liver Dis. 2003, 23 (4): 385-396. 10.1055/s-2004-815564.View ArticlePubMed
- Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, et al: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006, 12 (4): 410-416. 10.1038/nm1377.View ArticlePubMed
- Jacobs EM, Hendriks JC, van Tits BL, Evans PJ, Breuer W, Liu DY, Jansen EH, Jauhiainen K, Sturm B, Porter JB, et al: Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Anal Biochem. 2005, 341 (2): 241-250. 10.1016/j.ab.2005.03.008.View ArticlePubMed
- Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P: LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005, 18 (2): 277-287. 10.1016/j.beha.2004.10.003.View ArticlePubMed
- Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA: Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 1997, 388 (6641): 482-488. 10.1038/41343.View ArticlePubMed
- Mackenzie B, Ujwal ML, Chang MH, Romero MF, Hediger MA: Divalent metal-ion transporter DMT1 mediates both H+-coupled Fe2+ transport and uncoupled fluxes. Pflugers Arch. 2006, 451 (4): 544-558. 10.1007/s00424-005-1494-3.View ArticlePubMed
- Mims MP, Prchal JT: Divalent metal transporter 1. Hematology. 2005, 10 (4): 339-345. 10.1080/10245330500093419.View ArticlePubMed
- Trinder D, Oates PS, Thomas C, Sadleir J, Morgan EH: Localisation of divalent metal transporter 1 (DMT1) to the microvillus membrane of rat duodenal enterocytes in iron deficiency, but to hepatocytes in iron overload. Gut. 2000, 46 (2): 270-276. 10.1136/gut.46.2.270.PubMed CentralView ArticlePubMed
- Liuzzi JP, Aydemir F, Nam H, Knutson MD, Cousins RJ: Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc Natl Acad Sci USA. 2006, 103 (37): 13612-13617. 10.1073/pnas.0606424103.PubMed CentralView ArticlePubMed
- Liu Y, Zhu X, Zhu J, Liao S, Tang Q, Liu K, Guan X, Zhang J, Feng Z: Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. Oncol Rep. 2007, 18 (4): 943-951.PubMed
- Mwanjewe J, Grover AK: Role of transient receptor potential canonical 6 (TRPC6) in non-transferrin-bound iron uptake in neuronal phenotype PC12 cells. Biochem J. 2004, 378 (Pt 3): 975-982. 10.1042/BJ20031187.PubMed CentralView ArticlePubMed
- Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, Yazdanpanah M, Wilson GJ, Schwartz A, Liu PP, et al: L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003, 9 (9): 1187-1194. 10.1038/nm920.View ArticlePubMed
- Zhang Z, Huang C, Li J, Leonard SS, Lanciotti R, Butterworth L, Shi X: Vanadate-induced cell growth regulation and the role of reactive oxygen species. Arch Biochem Biophys. 2001, 392 (2): 311-320. 10.1006/abbi.2001.2464.View ArticlePubMed
- Leonard SS, Harris GK, Shi X: Metal-induced oxidative stress and signal transduction. Free Radic Biol Med. 2004, 37 (12): 1921-1942. 10.1016/j.freeradbiomed.2004.09.010.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/8/2/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.